While the role of ALK and ROS1 inhibitors is now established as standard of care among ALK - or ROS1 -positive NSCLC in addition to some of the rare tumors listed above, our data suggest that patients with other tumor types that harbor these mutations may also benefit from targeted therapy. The gene discussed is ALK; the disease is neoplasm.